Cardio-kidney-metabolic (CKM) disease often remains uncontrolled despite standard treatment, influenced by factors like adherence and unrecognized secondary causes. Hypercortisolism, encompassing mild autonomous cortisol secretion (MACS) to Cushing syndrome, is increasingly recognized as a contributing factor.
Hypercortisolism and Associated Risks
Elevated cortisol levels are linked to a significantly higher risk of cardiovascular death and increased prevalence of hypertension and type 2 diabetes mellitus (T2DM), alongside kidney impairment. This excess promotes insulin resistance, increased glucose production, β-cell dysfunction, sodium retention, and vascular changes, exacerbating CKM complications. Studies indicate hypercortisolism is more common than previously thought, observed in approximately 24% of patients with difficult-to-control T2DM and 27% in those with resistant hypertension. The overnight 1 mg dexamethasone suppression test is the preferred diagnostic method.
Diagnostic and Treatment Strategies
Treatment strategies involve adrenal steroidogenesis inhibitors, glucocorticoid receptor antagonists, and pituitary-directed therapies, with surgery being the initial approach for surgically correctable conditions. This review details the connection between cortisol excess and CKM dysfunction, emphasizing the need for clinical trials, standardized diagnostic criteria, and assays to incorporate cortisol-targeted therapies into management. The aim is to address residual CKM risk and provide a practical guide for cardiologists in managing this potentially reversible contributor to poor CKM control.